MG
ATRC icon

Michael Gelband’s AtriCure ATRC Stock Holding History

Michael Gelband’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-75,000
Closed -$2.52M – 1759
2020
Q1 		$2.52M Buy
+75,000
New +$2.7M 0.14% 147

Other funds holding ATRC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Michael Gelband's ATRC Position: Q2 2026 in Review

Michael Gelband opened a new position in AtriCure (ATRC) in Q2 2026: 86,356 shares worth $2.42M. The stake represents 0.02% of the portfolio and ranks #755 among its holdings. This is a return to the name: Michael Gelband previously reported a position in ATRC as recently as Q4 2025.

Michael Gelband first reported a position in ATRC in Q1 2020 and has held it in 16 quarters since. The position peaked at $10.5M in Q4 2021. 250 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

  • Michael Gelband held 86,356 shares of AtriCure worth $2.42M as of Q2 2026.
  • AtriCure was a new Michael Gelband position in Q2 2026.
  • AtriCure made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #755 holding.
  • Michael Gelband first reported a position in AtriCure in Q1 2020 and has held it in 16 quarters since.
  • Michael Gelband's AtriCure position peaked at $10.5M in Q4 2021.
  • 250 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.